Form 4: Altimmune's Chief Medical Officer Transfers Shares to Trust

Altimmune's Chief Medical Officer, Matthew Scott Harris, transferred 67,787 shares of common stock to the Matthew Scott Harris Trust on March 7, 2025.

Summary

• On March 7, 2025, Matthew Scott Harris, the Chief Medical Officer of Altimmune, Inc., transferred 67,787 shares of Altimmune common stock to the Matthew Scott Harris Trust.
• The transfer was made for no consideration.
• Harris is the trustee of the trust, and he and his immediate family are the sole beneficiaries.
• Despite the transfer, Harris remains the beneficial owner of the shares held by the trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding a share transfer to a trust, which is neutral in sentiment.

Industry Context

This is a routine disclosure related to insider transactions and doesn't necessarily reflect a strategic shift for Altimmune.

Related Party Transactions

• The transfer of shares to the Matthew Scott Harris Trust, of which Matthew Scott Harris is the trustee and beneficiary, constitutes a related party transaction.

Stakeholder Impact

• The transfer of shares to a trust by a key executive could be perceived as a neutral event by shareholders, as the executive retains beneficial ownership.

Key Dates